Recombinant Pelophylax ridibundus Brevinin-2Rc
Description
Table 1: Physicochemical Properties
| Property | Specification |
|---|---|
| Source | Recombinant (Yeast or E. coli) |
| Expression Region | Amino acids 1–25 |
| Purity | >85% (SDS-PAGE) |
| Shelf Life (Lyophilized) | 12 months at -20°C/-80°C |
Production and Recombinant Expression
Brevinin-2R is produced via recombinant DNA technology in two primary systems:
Table 2: Expression Systems Comparison
Both systems yield functional peptide with >85% purity, though yeast-derived versions may offer superior folding for certain applications .
Biological Activity and Mechanisms
Brevinin-2R exhibits unique bioactivity profiles:
Antimicrobial Effects
-
Broad-Spectrum Action: Effective against Gram-negative bacteria (e.g., Acinetobacter baumannii, MIC = 3–6 μM) and fungi .
-
Low Hemolytic Activity: <20% hemolysis at 20 μg/mL, unlike most Brevinins .
Anticancer Activity
Brevinin-2R induces caspase-independent apoptosis in cancer cells via:
Table 3: Cytotoxicity Against Cancer Cell Lines24
| Cell Line | IC₅₀ (μg/mL) | Mechanism |
|---|---|---|
| Jurkat | 10 | Lysosome-mitochondrial crosstalk |
| MCF-7 | 10 | ROS-mediated death |
| A549 | 20 | ATP depletion |
| HepG2 | 15 | IL-1β/IL-6 upregulation |
Notably, Brevinin-2R outperforms doxorubicin in cytotoxicity against Jurkat and MCF-7 cells at equivalent concentrations .
Advantages
-
Selective Toxicity: Minimal impact on normal cells (e.g., PBMCs, human T cells) due to preferential binding to anionic phosphatidylserines on cancer membranes .
-
Synergy with Chemotherapy: Enhances efficacy of cisplatin and doxorubicin in combinatorial regimens .
